ADVANCEMENTS IN THERAPEUTIC STRATEGIES: THE ROLE OF BMAL1 IN ENHANCING CEREBRAL GLIOMA ANGIOGENESIS IN ATHLETES THROUGH THE MODULATION OF VEGF AND ANG2

Abstract

Objective: This study aims to investigate the role of BMAL1 in promoting angiogenesis in cerebral glioma among athletes by regulating vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG2). Methods: Human brain tumor cells, representative of gliomas often observed in athletes, were categorized into three groups: blank, control, and BMAL1-treated research group. Cell growth and apoptosis were analyzed using the MTT assay and flow cytometry, respectively. VEGF and ANG2 expressions, along with microvessel density (MVD), were assessed via immunohistochemistry. The Spearman rank test evaluated the correlation between VEGF and ANG2 levels. Further, groups A, B, and C (representing different pathological grades of human glioma tissues) and BMAL1-treated groups (D, E, and F) were compared to analyze BMAL1's role in modulating VEGF and ANG2. Results: The control group showed significantly lower cell survival and higher apoptosis rates compared to the blank group (P<0.05). Higher glioma grades correlated positively with increased apoptosis rates (P><0.05). VEGF, ANG2, and MVD expressions were significantly higher in the control group than in the blank group (P><0.05), with notable differences observed between the study and control groups (P><0.05). A positive correlation was found between glioma grade, MVD count, and the expressions of VEGF and ANG2 (P><0.05). Groups D, E, and F demonstrated significant differences in VEGF and ANG2 expressions, with group F exhibiting the highest levels (P><0.05), indicating <0.05). Higher glioma grades correlated positively with increased apoptosis rates (P<0.05). VEGF, ANG2, and MVD expressions were significantly higher in the control group than in the blank group (P><0.05), with notable differences observed between the study and control groups (P><0.05). > <0.05). VEGF, ANG2, and MVD expressions were significantly higher in the control group than in the blank group (P<0.05), w> <0.05 ), with notable differences observed between the study and control groups (P<0.05). A positive correlation was found between glioma grade, MVD count, and the expressions of VEGF and ANG2 (P><0.05) A positive correlation was found between glioma grade, MVD count, and the expressions of VEGF and ANG2 (P<0.05). ><0.05 ). Groups D, E, and F demonstrated significant differences in VEGF and ANG2 expressions, with group F exhibiting the highest levels (P<0.05), indicating <0.05 ), indicating BMAL1's regulatory effect on these angiogenic factors. Conclusion: The study confirms that BMAL1 regulates VEGF and ANG2 expression, promoting angiogenesis in cerebral glioma, a condition relevant to athletes due to their unique physiological stresses. This highlights the potential of targeting BMAL1 in developing therapeutic strategies for glioma angiogenesis in athletic populations, providing a novel approach to manage this challenging aspect of cerebral glioma treatment.